ABOUT US
Introducing SML Biopharm, preparing for the future battle against life-threatening diseases.
Innovating Future Medicine
with mRNA Technology
SML Biopharm Co., Ltd. is a company specializing in mRNA-based vaccine and therapeutic development, established in 2021 through Professor Jae-Hwan Nam's university startup at Catholic University of Korea.
Experts with over 10 years of research experience in mRNA vaccines and immunoadjuvants have gathered to provide new treatment opportunities for patients suffering from diseases without treatments through differentiated mRNA platform technology.
Vision
Growing into a globally competitive biotech company utilizing mRNA technology, contributing to a healthy future for humanity.
Mission
Developing innovative therapeutics for various diseases with differentiated mRNA platform technology, providing new hope to patients suffering from untreatable diseases.
Jae-Hwan Nam
CEO / Professor at Catholic University of Korea
An Innovative Journey
for the Future
Jae-Hwan Nam
CEO, SML Biopharm Co., Ltd.
History
Key milestones of SML Biopharm.
MOU with Cha Vaccine Institute for mRNA Vaccine Co-development
MOU with Affilogic (France) for Targeted Drug Development
MOU with Probio for mRNA Development
MOU with CATUG (Switzerland) for mRNA Technology
Selected for MOHW Infectious Disease R&D Project
Acquired SFTS Neutralizing Antibody Sequence
Selected for MSIT Innovation Startup Package
CUK-SML Biomedical Center Opening
Series A Investment from Meritz Securities
Seed Investment from SML Labtree
SML Biopharm Established
Leadership
Meet the experts leading SML Biopharm.
Jae-Hwan Nam
CEO
Professor at Department of Medical and Biological Sciences, Catholic University of Korea. Over 10 years of experience in mRNA vaccine and immunoadjuvant research.
Dae-Keun Kim
Research Director & COO
Principal investigator of SFTS therapeutic development project. Oversees overall R&D as Chief Operating Officer.
Young-Chan An
Senior Researcher
Presented at European mRNA Conference. Leading SFTS antibody therapeutic development.
Partnership
We secure global competitiveness through collaboration with leading domestic and international institutions.
Probio
China / GlobalGenScript Biotech Group subsidiary. Comprehensive collaboration in mRNA development, production, and clinical research.
CATUG
SwitzerlandGlobal mRNA CRO/CDMO company. Collaboration in mRNA technology development and commercialization.
Affilogic
FranceOwns Nanofitin targeting protein technology. Joint development of next-generation targeted therapeutics.
Cha Vaccine Institute
KoreaCHA Biotech affiliate. MOU signed for joint development of mRNA-based vaccines and therapeutics.
Catholic University of Korea
KoreaOperating CUK-SML Biomedical Center. Industry-academia collaboration and joint research.
Ministry of Health and Welfare
Infectious Disease Prevention and Treatment R&DSFTS therapeutic development project. KRW 2.05 billion support over 3 years.
KDCA
National Institute of HealthAwarded project for securing SFTS therapeutic candidates.
Ministry of SMEs and Startups
Innovation Startup PackageSupport for promising companies in cutting-edge fields. Technology commercialization and R&D linkage support.
Group Companies
SML Biopharm is a member of the Samkwang Biotree Group (SML Group),<br>building an integrated bio-health ecosystem encompassing<br>diagnostic testing, clinical trials, genetic diagnostics, and new drug development.
Location
Contact Information
(Google Maps or Kakao Maps will be embedded)